- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, announced today that management will present a company overview.
Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, announced today that management will present a company overview at the following two upcoming conferences:
Merriman Curhan Ford 6th Annual Investor Summit
Date: Tuesday, November 10, 2009
Time: 10:00 a.m. EST
Location: Hotel Sofitel New York
Lazard Capital Markets 6th Annual Healthcare Conference
Date: Tuesday, November 17, 2009
Time: 9:25 a.m. EST
Location: The St. Regis hotel in New York
A live webcast of each presentation will be available in the Investor Relations section of the company's website at www.abraxisbio.com. The webcasts will be archived and accessible for at least 30 days.
About Abraxis BioScience
Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company's portfolio includes the world's first and only protein-bound nanoparticle chemotherapeutic compound (ABRAXANE®), which is based on the company's proprietary tumor targeting technology known as the nab® platform. The first FDA approved product to use this nab platform, ABRAXANE, was launched in 2005 for the treatment of metastatic breast cancer and is now approved in 38 countries. The company continues to expand the nab platform through a robust clinical program and deep product pipeline. Abraxis trades on the NASDAQ Global Market under the symbol ABII.
For more information, please click here
Investor & Media Inquiries
Abraxis BioScience, Inc.
Director Investor Relations & Corporate Communications
Rob Whetstone, 310-279-5963
Copyright © Abraxis BioScienceIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Call for NanoArt and Art-Science-Technology Papers June 9th, 2016
Novel gene therapy shows potential for lung repair in asthma May 18th, 2016